2'-methylguanosine

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2'-methylguanosine
• 英文别名: 2 inverted exclamation mark-O-Methylguanosine；2-amino-9-[4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-1H-purin-6-one
• 化学式: C₁₁H₁₅N₅O₅
• 分子量: 297.271
• InChiKey: OVYNGSFVYRPRCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  144
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  在 triethylamine tris(hydrogen fluoride) 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到2'-methylguanosine
  参考文献：
  名称：

  Reagent and process for protecting active groups

  摘要：

  具有除了双价氧以外的其他基团的硅基化试剂，在强韧条件下提供对反应基团的区域选择性保护，例如烷基化、酰化和脱氧等碱性条件。特别是，具有除氧以外的基团分隔两个硅基团的硅基化试剂对于保护核糖核酸或脱氧核糖核酸的两个羟基是有用的。在存在过量轻微阻碍碱（如钠HMDS）的情况下，可在创新的硅基化试剂保护的核糖核苷酸的2'-羟基上进行烷基化，而无需保护嘌呤碱基的外环胺基和羟基官能团。

  公开号：

  US20030225262A1

文献信息

• EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20180177814A1

  公开（公告）日：2018-06-28

  Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.

  抗义核苷酸寡聚体结合到人类肌营养不良基因中的特定靶位点，诱导外显子51跳跃。
• Exon skipping oligomer conjugates for muscular dystrophy
  申请人：Sarepta Therapeutics, Inc.

  公开号：US10765760B2

  公开（公告）日：2020-09-08

  Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.

  本研究描述了与人类肌营养不良症基因中选定的靶点互补的反义寡聚体共轭物，以诱导第 52 号外显子跳越。
• Profiling chemically modified DNA/RNA units for disease and cancer diagnosis
  申请人：The Research Foundation for The State University of New York

  公开号：US11339441B2

  公开（公告）日：2022-05-24

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MSn), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.

  本发明涉及高通量方法，包括直接注入电喷雾离子化质谱（ESI-MS）、多步串联质谱（MSn）、连续反应监测（CRM）、离子迁移谱质谱（IMS-MS）、高分辨率 MS 和 IMS-MS，用于对具有多种变异结构修饰的 DNA 和 RNA 核苷酸/核苷进行全基因组（全细胞或组织）分析。特别是，这些方法可用于提供与特定病症相关的变异 DNA 和/或 RNA 化学修饰核酸（即结构）的特定概况。病症可包括但不限于：癌症；包括前列腺癌、肺癌、子宫癌、喉癌、卵巢癌、乳腺癌、肾癌和许多其他类型的癌症；癌症的特定阶段；细菌感染；病毒感染；遗传和代谢紊乱；以及任何涉及 DNA 和/或 RNA 结构修饰变化的病症。
• PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS
  申请人：THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

  公开号：US20170044619A1

  公开（公告）日：2017-02-16

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MS n ), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.
• COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY
  申请人：SAREPTA THERAPEUTICS, INC.

  公开号：US20200254002A1

  公开（公告）日：2020-08-13

  The present disclosure relates to methods of treating Duchenne's Muscular Dystrophy by administering an antisense oligonucleotide that induces exon skipping and a non-steroidal anti-inflammatory compound.